ET-26

DRUG3 trials

Sponsors

Ahon Pharmaceutical Co., Ltd.

Conditions

Anesthesia InductionHepatic InsufficiencyInteraction Drug Food

Phase 1

Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride

Ahon Pharmaceutical Co., Ltd.Hepatic Insufficiency

Start: 2023-12-06End: 2024-04-30Target: 24Updated: 2023-12-20

Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride

CompletedNCT06822166

Ahon Pharmaceutical Co., Ltd.Interaction Drug Food

Start: 2023-12-04End: 2024-01-23Updated: 2025-02-14

Phase 3

A Trial to Evaluate the Efficacy and Safety of Methoxyetomidate Hydrochloride for Injection (ET-26) for the Induction of General Anesthesia in Elective Surgery Subjects

RecruitingNCT06203431

Ahon Pharmaceutical Co., Ltd.Anesthesia Induction

Start: 2023-10-11End: 2024-06-30Target: 270Updated: 2024-01-12

Related Papers

Pharmacokinetics, safety, and pharmacodynamics of intravenous methoxyethyl etomidate hydrochloride (ET-26-HCl) in Chinese participants with hepatic impairment

Frontiers in Pharmacology2026-07-30